Abraxis BioScience
Template:Short description Script error: No such module "Infobox".Script error: No such module "Check for conflicting parameters".Script error: No such module "Check for unknown parameters".
Abraxis BioScience was a global biopharmaceutical, and nano-medicine company that developed treatments for critically ill patients. It had over 2000 employees worldwide in 2007.[1] Abraxis's portfolio included the world's first protein-based nanoparticle chemotherapeutic compound, called nab Technology.[2] From this the company developed Abraxane, a treatment for metastatic breast cancer.[3]
In 2010, Abraxis BioScience was acquired by Celgene Corporation.[4]
History
Abraxis was incorporated in 2001 in Los Angeles.[5] It was formerly known as American Pharmaceutical Partners (APP), which as known for its injectable oncology, anti-infective and critical care.[6] Besides cancer treatments, it provided treatment for multiple sclerosis, Alzheimer's, and some cardiovascular diseases.[5] It had manufacturing plants in Melrose Park, Illinois and Phoenix, Arizona.[5] By 2005, Dr. Patrick Soon-Shiong merged American BioScience and the publicly-held APP, naming it Abraxis BioScience.[7] Under this new name, seventy-four trials were undertaken to test Abraxane against various cancer targets.[7] The drug, which was approved by the FDA in 2005, was the subject of a litigation (Elan Pharma v. Abraxis BioScience) for patent infringement.[8] In 2008, Abraxis was ordered to pay $55.2 million to Elan.[8]
In August 2007, Abraxis announced it would again undergo a restructuring to separate its "hospital-based products business" from its "proprietary products business" into two public companies; this would involve the merging of Abraxis Oncology and Abraxis Research sub-units to form a new Abraxis Bioscience (Abraxis Bioscience, Inc., Nasdaq: ABII), and the spinoff of Abraxis Pharmaceutical Products (APP, Inc., Nasdaq: APPX).[9] This reorganization was completed in November 2007.[10] During the reorganization, the new Abraxis Bioscience was known briefly as New Abraxis.[10]
In 2010, Abraxis BioScience was acquired by Celgene Corporation.[4] Per Celgene's website, as of at least 2016 Abraxis no longer exists as a named division within Celgene.Script error: No such module "Unsubst".
References
<templatestyles src="Reflist/styles.css" />
- ↑ BioPortfolio, 2007, "InDepth Summary", 10/11/2009Script error: No such module "Unsubst".
- ↑ Abraxis BioScience, 2008, "Nab Technology", 10/11/2009
- ↑ Hoovers. Script error: No such module "webarchive".
- ↑ a b Celgene, 30 June 2010, "Celgene To Acquire Abraxis BioScience Inc." (press release), 8/6/2015.
- ↑ a b c Cite error: Script error: No such module "Namespace detect".Script error: No such module "Namespace detect".
- ↑ Script error: No such module "citation/CS1".
- ↑ a b Script error: No such module "citation/CS1".
- ↑ a b Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ a b Script error: No such module "citation/CS1".
Script error: No such module "Check for unknown parameters".
External links
Script error: No such module "Portal".
- Pages with script errors
- Pages with reference errors
- Defunct biotechnology companies of the United States
- Defunct pharmaceutical companies of the United States
- Biotechnology companies established in 2001
- Pharmaceutical companies established in 2001
- 2001 establishments in California
- Biotechnology companies disestablished in 2010
- Pharmaceutical companies disestablished in 2010
- 2010 disestablishments in California
- Health care companies based in California
- 2010 mergers and acquisitions
- Defunct technology companies based in New York City
- American companies disestablished in 2010
- American companies established in 2001